Report Code: A10499 | Nov 2023 | Pages: NA | ||
Tables: NA | Charts: NA |
|
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Hunter’s Syndrome Market
Request Now !Hunter’s syndrome mucopolysaccharidosis type II (MPS II) is a rare genetic disorder in which large sugar molecules called glycosaminoglycans (GAGs) or mucopolysaccharides are produced in body tissues. It is observed to be a form of lysosomal storage disease. Hunter’ssyndrome is caused by the deficiency of lysosomal enzyme iduronate-2-sulfatase (I2S). The lack of this enzyme causes heparan sulfate and dermatan sulfate to accumulate in all body tissues. Hunter’ssyndrome is the only MPS syndrome to exhibit X-linked recessive inheritance. The symptoms of this syndrome are abdominal hernias, ear infections, runny nose, and cold. As the buildup of GAGs continues throughout the cells of the body, signs of MPS II become more visible.
COVID-19 scenarioanalysis
Key pharmaceutical and biotechnological companies have grouped together with governments such that they meet the current demand for medical supplies throughout the globe.Increase in demand has been witnessed for drugs, which presentspotential opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs.There are around 115 vaccine candidates and other 155 molecules that are advanced such that the research and development pipelines are updated in the coming years. The commonly used drugs such as hydroxychloroquine have seenhugeboost in demand for the management of COVID-19.Due to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expectedto grow significantly in the coming years.
Top impacting factors: market scenario analysis, trends, drivers, and impact analysis
The major factor affecting the industry include introduction of novel therapies, which would propel the growth of the industry in the coming years.Increase in increase in government initiatives and rise in awareness about Hunter’s syndrome fuelthe market growth during the forecast period.In addition, surge in number of mergers and acquisitions boosts the market growth in the upcoming years. However, implementation of stringent regulations for the manufacturing of drugs may hinder the growth of the industry.
Surge in number of patients
According to the National MPS Society, Hunter’s syndrome is a rare condition affecting 1 in 100,000 to 1 in 170,000, primarily males.Females may be carriers of the gene for MPS II. Although rare, MPS II has been diagnosed in girls. If the mother is a carrier, there is a 50% chance that any boy born will have the disease.
Sisters and maternal aunts of a person with MPS II may be carriers of the disease and would also have a 50% chance of passing the syndrome to son.Increase in the of patient population would positively impact the growth of the industry in the near future.
Surge in number of mergers and acquisitions
Increase in the number of mergers and acquisitions is anticipated toboost the industrygrowth in the coming years. For instance, in July 2014, ArmaGen, a privately held biotechnology company, announced that it had entered into a worldwide licensing and collaboration agreement with Shire Plc.to develop AGT-182, an investigational enzyme replacement therapy (ERT) for potential treatment of both the central nervous system (CNS) and somatic (body-related) manifestations of Hunter’s syndrome.
In 2014, Shire agreed a deal to buy the U.S.Company, Lumena Pharmaceuticals for $260m, bolstering its pipeline of rare disease candidates. Shire had itself been the subject of merger speculation with Allergan. Furthermore, buying Lumena would help provide two drugs in mid-stage clinical trials for rare liver diseases that will complement its own gastrointestinal drug portfolio. LUM001 and LUM002 are both inhibitors of the apical sodium-dependent bile acid transporter, or ASBT, and are being tested as treatments for cholestatic liver diseases, which occur when the flow of bile from the liver to the duodenum is reduced or blocked. ASBT is responsible for recycling bile acids back to the liver.
Key benefits of the report:
Questions answered in the Hunter’s syndrome market research report:
Hunter’s Syndrome Market Report Highlights
Aspects | Details |
---|---|
By Treatment Type |
|
By Route of Administration |
|
By Distribution Channel |
|
By Region |
|
Key Market Players | Takeda Pharmaceutical Company,, Inventiva S.A.,, ArmaGen Inc.,, JCR Pharmaceuticals Co Ltd.,, Denali Therapeutics Inc.,, RegenxBio Inc.,, Regenxbio, Sangamo Therapeutics, Inc.,, GC Pharma,, Bioasis Technologies Inc. |
Start reading.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers